Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY D BERTOLET

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1295845444
CMS profile
240622
Location
TUPELO, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$74,035.39

136 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY D BERTOLET

NPI 1295845444 · CMS profile ID 240622

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

TUPELO, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY D BERTOLET, NPI 1295845444, CMS profile ID 240622. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BARRY D BERTOLET, NPI 1295845444, CMS profile ID 240622. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BARRY D BERTOLET, NPI 1295845444, CMS profile ID 240622, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–136 of 136 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1295845444?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

136 matching records · $74,035.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 136 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–136 of 136.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Esperion Therapeutics, Inc. $1,500.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838247007 CMS
AstraZeneca Pharmaceuticals LP $15.8104/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834330877 CMS
Esperion Therapeutics, Inc. $1,500.0004/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838247003 CMS
Esperion Therapeutics, Inc. $16.1104/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838246999 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $9.4204/07/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763358826 CMS
Esperion Therapeutics, Inc. $1,980.0004/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838246995 CMS
Janssen Pharmaceuticals, Inc $15.3804/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788088643 CMS
CARDIVA MEDICAL, INC. $1,875.0004/01/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839389821 CMS
Merck Sharp & Dohme Corporation $16.0704/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848692791 CMS
AstraZeneca Pharmaceuticals LP $18.5003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834326353 CMS
Osprey Medical Inc $7.8403/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 760866664 CMS
BOSTON SCIENTIFIC CORPORATION $81.4303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777759221 CMS
ABIOMED $25.4203/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848770247 CMS
ABIOMED $142.7903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848770249 CMS
AstraZeneca Pharmaceuticals LP $55.3503/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834343051 CMS
Shockwave Medical, Inc $750.0003/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853181715 CMS
Shockwave Medical, Inc $10.0403/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853185243 CMS
AstraZeneca Pharmaceuticals LP $100.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834323137 CMS
AstraZeneca Pharmaceuticals LP $100.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834346077 CMS
AstraZeneca Pharmaceuticals LP $100.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834351253 CMS
AstraZeneca Pharmaceuticals LP $3,200.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834339623 CMS
Shockwave Medical, Inc $20.7603/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853182975 CMS
ABIOMED $9.2003/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848770245 CMS
Merck Sharp & Dohme Corporation $16.9302/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848318129 CMS
Amarin Pharma Inc. $15.4102/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815300015 CMS
Medicure Pharma Inc. $800.0002/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827906121 CMS
Osprey Medical Inc $14.5302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 760866670 CMS
W. L. Gore & Associates, Inc. $78.0502/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844665139 CMS
AstraZeneca Pharmaceuticals LP $19.4702/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834333149 CMS
AstraZeneca Pharmaceuticals LP $60.4802/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834340939 CMS
AstraZeneca Pharmaceuticals LP $99.4102/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834344137 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.9301/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763358824 CMS
Amgen Inc. $467.0001/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825172767 CMS
Amgen Inc. $2,800.0001/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825172775 CMS
Amgen Inc. $94.0801/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825172771 CMS
Amgen Inc. $94.2101/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825172779 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $51,545.86 126
PY2020 $95,273.39 134
PY2021 $74,035.39 136
PY2022 $33,671.42 145
PY2023 $66,575.92 157
PY2024 $68,076.04 189
PY2025 $80,074.55 217

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,227,874.34 73
PY2024 Recipient $4,144.67 1
PY2024 Principal investigator $1,889,813.70 86
PY2023 Principal investigator $799,184.76 96
PY2022 Principal investigator $522,959.51 138
PY2021 Principal investigator $604,820.57 137
PY2020 Recipient $6,500.00 1
PY2020 Principal investigator $395,382.59 79
PY2019 Principal investigator $496,886.73 73

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Medtronic, Inc. $98,205.00 12/31/2025 Non-covered Recipient Entity
Cardiology Associates Of North Ms Pa
SPYRAL AFFIRM No dispute reported 06/30/2026 1185005682
Principal investigator 1 Boston Scientific Corporation $1,630.00 12/16/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571509
Principal investigator 1 Janssen Research & Development, LLC $8,068.00 12/12/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237781
Principal investigator 1 Medtronic, Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL HTN-ON MED Expan No dispute reported 06/30/2026 1192317202
Principal investigator 1 Shockwave Medical, Inc $1,300.00 11/24/2025 Covered Recipient Teaching Hospital
North Mississippi Medical Center
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055767
Principal investigator 1 Janssen Research & Development, LLC $10,477.00 11/19/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237738
Principal investigator 1 Medtronic, Inc. $1.00 11/10/2025 Non-covered Recipient Entity
North Mississippi Medical Center
SPYRAL AFFIRM No dispute reported 06/30/2026 1185005737
Principal investigator 1 Janssen Research & Development, LLC $16,607.00 11/07/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237755
Principal investigator 1 Medtronic, Inc. $5,090.00 11/07/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319020
Principal investigator 1 Boston Scientific Corporation $1,220.00 11/04/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,500.00 10/24/2025 Non-covered Recipient Entity
Cardiology Associates of North Mississippi PA
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215508792
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 10/24/2025 Non-covered Recipient Entity
Cardiology Associates of North Mississippi PA
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215508797
Principal investigator 1 Boston Scientific Corporation $4,160.00 10/21/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571505
Principal investigator 1 Medtronic, Inc. $73,700.00 10/17/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319016
Principal investigator 1 Medtronic, Inc. $2,100.00 10/17/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319018
Principal investigator 1 Amgen Inc. $563.10 10/08/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246639965
Principal investigator 1 Medtronic, Inc. $555.00 09/26/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL HTN-ON MED Expan No dispute reported 06/30/2026 1192317200
Principal investigator 1 Medtronic, Inc. $66,339.00 09/26/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL AFFIRM No dispute reported 06/30/2026 1192326223
Principal investigator 1 Amgen Inc. $1,555.14 09/24/2025 Non-covered Recipient Entity
ARDIOLOGY ASSOCIATES OF NORTH MS PA
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246639175
Principal investigator 1 Janssen Research & Development, LLC $14,501.00 09/19/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237723
Principal investigator 1 Medtronic, Inc. $1,820.00 09/12/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319012
Principal investigator 1 Medtronic, Inc. $1,500.00 09/12/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319014
Principal investigator 1 Boston Scientific Corporation $2,610.00 09/09/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571503
Principal investigator 1 Medtronic, Inc. $1,738.93 09/05/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319010
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,591.16 09/02/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190309888
Principal investigator 1 Novartis Pharmaceuticals Corporation $87,578.76 09/02/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309892
Principal investigator 1 Janssen Research & Development, LLC $12,742.00 08/25/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237732
Principal investigator 1 Boston Scientific Corporation $275.00 08/05/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
LUX-DX TRENDS No dispute reported 06/30/2026 1207571459
Principal investigator 1 Boston Scientific Corporation $2,865.00 08/05/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571501
Principal investigator 1 Janssen Research & Development, LLC $11,241.00 07/23/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237681
Principal investigator 1 Medtronic, Inc. $32,483.00 07/11/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319008
Principal investigator 1 Medtronic, Inc. $3.00 07/09/2025 Non-covered Recipient Entity
North Mississippi Medical Center
SPYRAL AFFIRM No dispute reported 06/30/2026 1185005729
Principal investigator 1 Boston Scientific Corporation $950.00 07/08/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
LUX-DX TRENDS No dispute reported 06/30/2026 1207571457
Principal investigator 1 Boston Scientific Corporation $2,860.00 07/08/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571499
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 07/07/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175237700
Principal investigator 1 Medtronic, Inc. $33,732.00 07/03/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL AFFIRM No dispute reported 06/30/2026 1192326221
Principal investigator 1 Shockwave Medical, Inc $955.89 07/02/2025 Covered Recipient Teaching Hospital
North Mississippi Medical Center
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055753
Principal investigator 1 Medtronic, Inc. $3,500.00 06/27/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319004
Principal investigator 1 Medtronic, Inc. $5,460.00 06/27/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319006
Principal investigator 1 Janssen Research & Development, LLC $12,193.00 06/23/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237764
Principal investigator 1 Janssen Research & Development, LLC $16,048.00 06/20/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237716
Principal investigator 1 Medtronic, Inc. $555.00 06/20/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL HTN-ON MED Expan No dispute reported 06/30/2026 1192317198
Principal investigator 1 Boston Scientific Corporation $3,785.00 06/17/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571497
Principal investigator 1 Medtronic, Inc. $93.00 06/12/2025 Non-covered Recipient Entity
North Mississippi Medical Center
SPYRAL AFFIRM No dispute reported 06/30/2026 1185005725
Principal investigator 1 Shockwave Medical, Inc $955.89 05/30/2025 Covered Recipient Teaching Hospital
North Mississippi Medical Center
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055774
Principal investigator 1 Shockwave Medical, Inc $2,500.00 05/22/2025 Non-covered Recipient Entity
Cardiology Associates Research
Forward-Shifted Intravascular Lithotripsy (IVL) Technology in a Prospective, Multi-center, Single-arm Investigational Device Exemption (IDE) Study No dispute reported 06/30/2026 1175052745
Principal investigator 1 Janssen Research & Development, LLC $13,021.00 05/21/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237690
Principal investigator 1 Boston Scientific Corporation $635.00 05/13/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571495
Principal investigator 1 Janssen Research & Development, LLC $19,499.00 04/23/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237771
Principal investigator 1 Boston Scientific Corporation $150.00 04/22/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571481
Principal investigator 1 Boston Scientific Corporation $1,135.00 04/22/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571483
Principal investigator 1 Boston Scientific Corporation $25,875.00 04/22/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571493
Principal investigator 1 Medtronic, Inc. $378.00 03/28/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319002
Principal investigator 1 Shockwave Medical, Inc $955.89 03/27/2025 Covered Recipient Teaching Hospital
North Mississippi Medical Center
Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries No dispute reported 06/30/2026 1175055744
Principal investigator 1 Boston Scientific Corporation $275.00 03/25/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
LUX-DX TRENDS No dispute reported 06/30/2026 1207571455
Principal investigator 1 Boston Scientific Corporation $3,120.00 03/25/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571491
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,430.07 03/24/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190309890
Principal investigator 1 Janssen Research & Development, LLC $19,493.00 03/21/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237748
Principal investigator 1 Medtronic, Inc. $55,559.00 03/21/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL AFFIRM No dispute reported 06/30/2026 1192326219
Principal investigator 1 Medtronic, Inc. $1,000.00 03/14/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL AFFIRM No dispute reported 06/30/2026 1192326217
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,703.00 02/27/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI, PA
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302321
Principal investigator 1 Janssen Research & Development, LLC $16,625.00 02/19/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237707
Principal investigator 1 Boston Scientific Corporation $2,185.00 02/11/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571489
Principal investigator 1 Medtronic, Inc. $5.00 02/11/2025 Non-covered Recipient Entity
North Mississippi Medical Center
SPYRAL AFFIRM No dispute reported 06/30/2026 1185005722
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,564.00 01/30/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI, PA
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190302319
Principal investigator 1 Boston Scientific Corporation $550.00 01/28/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
LUX-DX TRENDS No dispute reported 06/30/2026 1207571453
Principal investigator 1 Novartis Pharmaceuticals Corporation $89,883.51 01/27/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309894
Principal investigator 1 Medtronic, Inc. $131,448.00 01/24/2025 Non-covered Recipient Entity
Cardiology Association Research Llc
SPYRAL AFFIRM No dispute reported 06/30/2026 1192326215
Principal investigator 1 Janssen Research & Development, LLC $47,797.00 01/22/2025 Non-covered Recipient Entity
Crdlgy Associates Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175237674
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $111,086.00 01/17/2025 Non-covered Recipient Entity
Urology Prof Assoc
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) (DISCOVER-HCM) No dispute reported 06/30/2026 1235992283
Principal investigator 1 Boston Scientific Corporation $3,535.00 01/14/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571485
Principal investigator 1 Boston Scientific Corporation $2,300.00 01/14/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES RESEARCH LLC
ELEGANCE No dispute reported 06/30/2026 1207571487
Principal investigator 1 Novartis Pharmaceuticals Corporation $60.00 01/01/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES OF NORTH MISSISSIPPI
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1190309898